Pingfu Fu

Pingfu Fu

Case Western Reserve University

H-index: 57

North America-United States

About Pingfu Fu

Pingfu Fu, With an exceptional h-index of 57 and a recent h-index of 39 (since 2020), a distinguished researcher at Case Western Reserve University, specializes in the field of biostatistics, clinical trial, oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignancies

Abstract PO5-17-08: Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer

Abstract PO3-04-04: Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy

PD42-06 CXC MOTIF CHEMOKINE RECEPTOR AS A DIFFERENTIAL BIOMARKER IN RACIAL DISPARITIES OF PROSTATE CANCER

Patients on Antithrombotic Agents with Small Bowel Bleeding–Yield of Small Bowel Capsule Endoscopy and Subsequent Management

Pingfu Fu Information

University

Position

___

Citations(all)

12097

Citations(since 2020)

5272

Cited By

8604

hIndex(all)

57

hIndex(since 2020)

39

i10Index(all)

174

i10Index(since 2020)

129

Email

University Profile Page

Google Scholar

Pingfu Fu Skills & Research Interests

biostatistics

clinical trial

oncology

Top articles of Pingfu Fu

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial

Transplantation and Cellular Therapy

2024/1/19

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Clinical Cancer Research

2024/1/5

A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Blood Advances

2024/1/5

Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignancies

Communications Medicine

2024/1/3

Abstract PO5-17-08: Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer

Cancer Research

2024/5/2

Abstract PO3-04-04: Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy

Cancer Research

2024/5/2

PD42-06 CXC MOTIF CHEMOKINE RECEPTOR AS A DIFFERENTIAL BIOMARKER IN RACIAL DISPARITIES OF PROSTATE CANCER

The Journal of Urology

2024/5

Patients on Antithrombotic Agents with Small Bowel Bleeding–Yield of Small Bowel Capsule Endoscopy and Subsequent Management

Digestive Diseases and Sciences

2024/4/18

Pingfu Fu
Pingfu Fu

H-Index: 35

Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis

JAMA oncology

2024/3/28

Pingfu Fu
Pingfu Fu

H-Index: 35

Artificial intelligence derived features of collagen architecture identify high risk HPV associated oropharyngeal squamous cell carcinoma patients

Cancer Research

2024/3/22

Differentially expressed genes as prognostic markers in racial disparities of prostate cancer

Cancer Research

2024/3/22

Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity

Circulation: Heart Failure

2024/2/13

Rank acquisition impact on radiomics estimation (AсquIRE) in chest CT imaging: A retrospective multi-site, multi-use-case study

Computer methods and programs in biomedicine

2024/2/1

Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

NPJ Breast Cancer

2023/5/17

Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens

Frontiers in Oncology

2023/5/3

Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV

Cancer Medicine

2023/5

Pingfu Fu
Pingfu Fu

H-Index: 35

A pathomic study for risk stratification and unraveling molecular associations of different histologic subtypes of papillary thyroid cancer

2023/4/6

Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with …

Cancer Research

2023/3/1

HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.

2023/2/20

Retinoblastoma expression and targeting by CDK4/6 inhibitors in small cell lung cancer

Molecular cancer therapeutics

2023/2/1

Michael Yang
Michael Yang

H-Index: 0

Pingfu Fu
Pingfu Fu

H-Index: 35

See List of Professors in Pingfu Fu University(Case Western Reserve University)

Co-Authors

academic-engine